| 1. | Kuga Ayumi, Tsuchida Kouhei, Panda Harit, et al. The β -TrCP-Mediated Pathway Cooperates with the Keap1-Mediated Pathway in Nrf2 Degradation In Vivo. Molecular and Cellular Biology. 2022; 42 (7): 1-22. doi:10.1128/mcb.00563-21 | ||
| 2. | Saigusa Daisuke, Motoike Ikuko N., Saito Sakae, et al. Impacts of NRF2 activation in non–small‐cell lung cancer cell lines on extracellular metabolites. Cancer Science. 2020; 111 (2): 667-678. doi:10.1111/cas.14278 | ||
| 3. | Keleku-Lukwete Nadine, Suzuki Mikiko, Panda Harit, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Advances. 2019; 3 (8): 1285-1297. doi:10.1182/bloodadvances.2018017574 | ||
| 4. | Katayama Saori, Suzuki Mikiko, Yamaoka Ayaka, et al. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis. Blood. 2017; 130 (7): 908-919. doi:10.1182/blood-2016-12-756767 | ||
| 5. | Tsuchida Kouhei, Tsujita Tadayuki, Hayashi Makiko, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radical Biology and Medicine. 2017; 103 : 236-247. doi:10.1016/j.freeradbiomed.2016.12.041 | ||
| 6. | Otsuki Akihito, Suzuki Mikiko, Katsuoka Fumiki, et al. Unique cistrome defined as CsMBE is strictly required for Nrf2-sMaf heterodimer function in cytoprotection. Free Radical Biology and Medicine. 2016; 91 : 45-57. doi:10.1016/j.freeradbiomed.2015.12.005 | ||
| 7. | Keleku-Lukwete Nadine, Suzuki Mikiko, Otsuki Akihito, et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proceedings of the National Academy of Sciences. 2015; 112 (39): 12169-12174. doi:10.1073/pnas.1509158112 | ||
| 8. | Yamazaki Hiromi, Suzuki Mikiko, Otsuki Akihito, et al. A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression. Cancer Cell. 2014; 25 (4): 415-427. doi:10.1016/j.ccr.2014.02.008 |